Comparative analysis of radiosensitizers for K-RAS mutant rectal cancers.

Approximately 40% of rectal cancers harbor activating K-RAS mutations, and these mutations are associated with poor clinical response to chemoradiotherapy. We aimed to identify small molecule inhibitors (SMIs) that synergize with ionizing radiation (IR) ("radiosensitizers") that could be i...

Full description

Bibliographic Details
Main Authors: Laura B Kleiman, Angela M Krebs, Stephen Y Kim, Theodore S Hong, Kevin M Haigis
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3861465?pdf=render